Juno Therapeutics (JUNO) Misses Q3 EPS by 2c

November 9, 2016 4:13 PM EST
Get Alerts JUNO Hot Sheet
Trade JUNO Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Juno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.57), $0.02 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $10.63 million.

Cash, cash equivalents, and marketable securities as of September 30, 2016 were $1.04 billion compared to $1.11 billion as of June 30, 2016 and $1.22 billion as of December 31, 2015.

Juno Therapeutics reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment